Pharmafile Logo
Pharmafocus logo
Advanced Search

Eylea

Showing 9 posts of 39 posts found.

eylea-product-box-md

Eylea receives new European approval

August 30, 2013
Research and Development, Sales and Marketing Bayer, CRVO, Eylea, Lucentis, Novartis, wet AMD

News
Eylea image

Eylea trial boost in DME

August 7, 2013
Research and Development, Sales and Marketing Bayer, DME, Eylea, regenenron

The rival treatment to Novartis’ Lucentis has posted encouraging new study results in patients with diabetic macular oedema (DME). In …

News
lucentis

New price and data changes NICE view on Lucentis

January 4, 2013
Sales and Marketing Bayer, Eylea, Lucentis, NICE, Novartis

A new lower price and new data analysis has persuaded NICE to recommend Lucentis for patients with diabetic macular oedema …

News
Eylea image

Eylea approval for wet AMD

November 29, 2012
Sales and Marketing Bayer, Eylea, Lucentis, Novartis, avastin, wet AMD

Bayer HealthCare’s Eylea has been appoved in Europe for the treatment of neovascular age-related macular degeneration (wet AMD). The eye …

News
Lucentis image

Lucentis gains new licence in the US

August 13, 2012
Sales and Marketing Eylea, FDA, Lucentis, approval, avastin, wet AMD

Roche’s eye drug Lucentis has gained a new licence in the US to treat diabetic macular oedema. The FDA has …

News

Regeneron to expand workforce at New York facility

August 8, 2012
Manufacturing and Production Arcalyst, Eylea, Regeneron, Zaltrap

Buoyant product sales at US biotech Regeneron have prompted the company to undertake a recruitment drive at its manufacturing facility …

News
caprelsa image

Major new drugs for 2012

March 9, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Caprelsa, Eylea, Manjor new drugs, Xalkori, Zelboraf, avastin, inlyta

 Renal cell carcinoma Pfizer’s Inlyta (axitinib) has been approved as second line treatment for renal cell carcinoma. The drug is …

Feature
Gilenya picture

Key product launches of 2011

December 19, 2011
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products

 Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …

Feature
Eylea picture

Lucentis rival gains US approval

November 22, 2011
Research and Development, Sales and Marketing Bayer, Eylea, Lucentis, Novartis, Regeneron, Roche

A rival to Roche and Novartis’ drug Lucentis has received FDA approval for a common form of eye disease. Eylea …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026